Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Therapeutics Inc (NQ: APLT )

1.129 +0.039 (+3.62%)
Streaming Delayed Price Updated: 9:56 AM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,141
Open 1.120
Bid (Size) 1.120 (27)
Ask (Size) 1.140 (7)
Prev. Close 1.090
Today's Range 1.120 - 1.140
52wk Range 0.4995 - 2.800
Shares Outstanding 48,058,956
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Applied Therapeutics Shares Are Seeing Blue Skies
Applied Therapeutics Inc (NASDAQ: APLT) shares are trading higher by 15.99% to $0.87 Wednesday morning after the company announced a partnership with Advanz Pharma for the commercialization of AT-007... 
Via Benzinga

Performance

YTD
+50.16%
+50.16%
1 Month
+26.06%
+26.06%
3 Month
+56.87%
+56.87%
6 Month
-16.95%
-16.95%
1 Year
-56.56%
-56.56%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Recap: Applied Therapeutics Q2 Earnings
Via Benzinga
Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe
From Applied Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Applied Therapeutics Reports Third Quarter 2022 Financial Results
From Applied Therapeutics
Via Globe NewsWire
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022
From Applied Therapeutics
Via Globe NewsWire
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy
From Applied Therapeutics
Via Globe NewsWire
Helbiz And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
Via Benzinga
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Via Benzinga
Why Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
Dow Dips Over 300 Points; Provention Bio Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Nasdaq Edges Higher; AngioDynamics Shares Plummet
Via Benzinga
Applied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical Significance
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format
From Applied Therapeutics
Via Globe NewsWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
TransDigm Group To $740? Also Check Out Some Other Major PT Changes
Via Benzinga
Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference
From Applied Therapeutics
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.